Oral antidiabetic drugs (for primary care physician
•Download as PPSX, PDF•
7 likes•530 views
This document summarizes different classes of oral antidiabetic drugs for primary care physicians. It describes biguanides like metformin, sulfonylureas like glibenclamide, alpha-glucosidase inhibitors like acarbose, and thiazolidinediones like pioglitazone. For each class, it provides information on indications, dosing, contraindications, and other details relevant to prescribing the drugs for treatment of type 2 diabetes. The document also lists additional resources on oral antidiabetics.
Report
Share
Report
Share
Recommended
Diabetes Drugs
This document summarizes different classes of drugs used to treat diabetes, including their mechanisms of action, effects, clinical applications, pharmacokinetics, and toxicities. The main classes discussed are insulins, sulfonylureas, glitinides, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, and incretin-based drugs. Insulins are used to treat type 1 and type 2 diabetes by activating insulin receptors and reducing blood glucose levels. Common side effects include hypoglycemia and weight gain. Sulfonylureas and glitinides are insulin secretagogues used for type 2 diabetes that close potassium channels on beta cells to increase insulin release, while
Sitagliptin
This document discusses the treatment of diabetes with a focus on the drug Sitagliptin. It provides details on Sitagliptin's mechanism of action as an inhibitor of DPP-4, pharmacokinetics, clinical efficacy in reducing HbA1c and glucose levels, safety profile, recommended dosage, drug interactions, and regulatory approval history. Sitagliptin represents an effective newer treatment option for type 2 diabetes with a good tolerability profile.
Diabetes mellitus amol
This document discusses the drug management of diabetes mellitus. It begins by classifying the different types of diabetes and criteria for diagnosis. It then discusses the therapeutic aims of glycemic control and treatment of associated conditions. The main therapeutic strategies discussed are medical nutrition therapy, exercise, and pharmacologic therapy including insulin for type 1 diabetes and oral glucose lowering agents or insulin for type 2 diabetes. Finally, it summarizes the mechanisms and examples of common classes of oral glucose lowering drugs including sulfonylureas, meglitinides, biguanides, and alpha-glucosidase inhibitors.
Newer anti diabetic drugs
The document discusses newer developments in treatments for diabetes. It describes several new classes of anti-diabetic drugs that target different pathways involved in blood glucose regulation, including DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and amylin analogs. It also discusses newer insulin formulations like Glargine U-300 and technologies under development like oral insulin, smart insulin patches, and an artificial pancreas using a dual hormone approach.
Drugs for treatment of Diabetes Mellitus
These slides contain the brief description of Insulin and the other oral drugs indicated in the treatment of Diabetes Mellitus. Their mechanism of action, effects, uses, Adverse effects etc.
Antidiabetic agent
This document provides an overview of antidiabetic agents including insulin and oral medications used to treat type 2 diabetes. It discusses the aims of diabetes management including achieving near-normal glycemia to prevent short and long-term complications. It then describes the types of insulin including rapid, short, intermediate and long-acting varieties. The document also summarizes the classes of oral medications including their mechanisms of action, efficacy, side effects and examples of drugs from each class. Combination therapy approaches are briefly outlined.
Dpp – 4 inhibitors
DPP-4 inhibitors work by inhibiting the breakdown of the incretin hormones GLP-1 and GIP, prolonging their effects and enhancing insulin secretion. They reduce blood glucose levels with a low risk of hypoglycemia and are weight neutral. Several DPP-4 inhibitors are available or in development for treating type 2 diabetes, including sitagliptin, saxagliptin, and linagliptin. DPP-4 inhibitors offer an effective treatment either alone or in combination with other drugs, with advantages like fewer side effects, safety in hepatic or renal impairment, and possible cardiovascular benefits. More research is still needed to fully evaluate their long-term safety profile.
Diabetes and new anti diabetic drugs
This document discusses diabetes and new antidiabetic drugs. It notes that diabetes cases are rising significantly worldwide and that diabetes increases the risk of serious health complications. It describes the different types of diabetes and their presentations. It recommends screening guidelines for prediabetes and notes the importance of lifestyle changes to prevent progression to diabetes. It discusses treatment targets and factors like hypoglycemia. It also provides an overview of various drug classes used to treat diabetes, including their mechanisms and effects.
Recommended
Diabetes Drugs
This document summarizes different classes of drugs used to treat diabetes, including their mechanisms of action, effects, clinical applications, pharmacokinetics, and toxicities. The main classes discussed are insulins, sulfonylureas, glitinides, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, and incretin-based drugs. Insulins are used to treat type 1 and type 2 diabetes by activating insulin receptors and reducing blood glucose levels. Common side effects include hypoglycemia and weight gain. Sulfonylureas and glitinides are insulin secretagogues used for type 2 diabetes that close potassium channels on beta cells to increase insulin release, while
Sitagliptin
This document discusses the treatment of diabetes with a focus on the drug Sitagliptin. It provides details on Sitagliptin's mechanism of action as an inhibitor of DPP-4, pharmacokinetics, clinical efficacy in reducing HbA1c and glucose levels, safety profile, recommended dosage, drug interactions, and regulatory approval history. Sitagliptin represents an effective newer treatment option for type 2 diabetes with a good tolerability profile.
Diabetes mellitus amol
This document discusses the drug management of diabetes mellitus. It begins by classifying the different types of diabetes and criteria for diagnosis. It then discusses the therapeutic aims of glycemic control and treatment of associated conditions. The main therapeutic strategies discussed are medical nutrition therapy, exercise, and pharmacologic therapy including insulin for type 1 diabetes and oral glucose lowering agents or insulin for type 2 diabetes. Finally, it summarizes the mechanisms and examples of common classes of oral glucose lowering drugs including sulfonylureas, meglitinides, biguanides, and alpha-glucosidase inhibitors.
Newer anti diabetic drugs
The document discusses newer developments in treatments for diabetes. It describes several new classes of anti-diabetic drugs that target different pathways involved in blood glucose regulation, including DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and amylin analogs. It also discusses newer insulin formulations like Glargine U-300 and technologies under development like oral insulin, smart insulin patches, and an artificial pancreas using a dual hormone approach.
Drugs for treatment of Diabetes Mellitus
These slides contain the brief description of Insulin and the other oral drugs indicated in the treatment of Diabetes Mellitus. Their mechanism of action, effects, uses, Adverse effects etc.
Antidiabetic agent
This document provides an overview of antidiabetic agents including insulin and oral medications used to treat type 2 diabetes. It discusses the aims of diabetes management including achieving near-normal glycemia to prevent short and long-term complications. It then describes the types of insulin including rapid, short, intermediate and long-acting varieties. The document also summarizes the classes of oral medications including their mechanisms of action, efficacy, side effects and examples of drugs from each class. Combination therapy approaches are briefly outlined.
Dpp – 4 inhibitors
DPP-4 inhibitors work by inhibiting the breakdown of the incretin hormones GLP-1 and GIP, prolonging their effects and enhancing insulin secretion. They reduce blood glucose levels with a low risk of hypoglycemia and are weight neutral. Several DPP-4 inhibitors are available or in development for treating type 2 diabetes, including sitagliptin, saxagliptin, and linagliptin. DPP-4 inhibitors offer an effective treatment either alone or in combination with other drugs, with advantages like fewer side effects, safety in hepatic or renal impairment, and possible cardiovascular benefits. More research is still needed to fully evaluate their long-term safety profile.
Diabetes and new anti diabetic drugs
This document discusses diabetes and new antidiabetic drugs. It notes that diabetes cases are rising significantly worldwide and that diabetes increases the risk of serious health complications. It describes the different types of diabetes and their presentations. It recommends screening guidelines for prediabetes and notes the importance of lifestyle changes to prevent progression to diabetes. It discusses treatment targets and factors like hypoglycemia. It also provides an overview of various drug classes used to treat diabetes, including their mechanisms and effects.
Anti diabetic drugs by Sanan Edrees
1) There are several classes of anti-diabetic drugs that treat diabetes mellitus by lowering blood glucose levels, including insulin secretagogues, insulin sensitizers, alpha-glucosidase inhibitors, and DPP-4 inhibitors.
2) Insulin secretagogues like sulfonylureas stimulate insulin release from the pancreas. Insulin sensitizers like biguanides and thiazolidinediones improve target cell response to insulin without increasing secretion.
3) Alpha-glucosidase inhibitors prevent carbohydrate digestion and absorption, reducing post-meal blood sugar spikes. DPP-4 inhibitors prolong incretin hormone activity, increasing insulin release and reducing glucagon levels in response to meals.
Corticosteroids
This ppt discusses pharmacological actions, toxic effects and clinical applications of corticosteroids. It also mentions precations to be taken while using steroids
Pharmacology of antidiabetic drugs
This document summarizes a lecture on pharmacology of antidiabetic drugs. It begins with an introduction to diabetes mellitus and its classification into four main types: type 1 characterized by insulin deficiency; type 2 characterized by insulin resistance and relative insulin deficiency; type 3 characterized by other specific causes; and type 4 or gestational diabetes. It then discusses the mechanisms and pharmacokinetics of various classes of antidiabetic drugs including insulin, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors and incretin mimetics. Adverse effects including hypoglycemia are also summarized.
Sodium glucose co transporter( SGLT2) Inhibitors
This document discusses sodium-glucose co-transporter 2 (SGLT2) inhibitors, a new class of drugs for treating type 2 diabetes. SGLT2 inhibitors work by blocking glucose reabsorption in the kidney, increasing urinary glucose excretion in a glucose-dependent manner. Three SGLT2 inhibitors have been approved by the FDA - canagliflozin, dapagliflozin, and empagliflozin. SGLT2 inhibitors offer advantages over other anti-diabetic drugs in that they are non-insulin dependent and can be used throughout the course of diabetes. However, long-term safety studies are still needed to fully assess their risk-benefit profile.
Beta blockers
Lecture on beta blockers their classification, therapeutic uses, adverse effects , contraindications.
Beta 2 agonists
This document outlines the structure and function of beta-2 agonists used to treat asthma. It discusses how modifications to the chemical structure can prolong the duration of action. It also describes the intracellular signaling pathway of beta-2 agonists and their mechanisms of action, including relaxation of airway smooth muscle. The document summarizes the pharmacologic attributes and differences between short-acting beta-2 agonists like albuterol and long-acting ones like formoterol and salmeterol. It discusses potential non-bronchodilator effects and issues of tolerance with regular use. The document concludes by outlining some clinical applications and safety studies of beta-2 agonists.
Pharmacotherapy of diabetes mellitus
This document summarizes the pharmacotherapy of diabetes mellitus. It discusses the classification, diagnosis, and pathophysiology of diabetes. It also describes the types of insulin preparations including human insulin, insulin analogs, and their mechanisms of action and indications. The document provides examples of insulin dosing regimens for type 1 diabetes, including an example case of calculating the initial daily insulin dose for a 14-year-old patient presenting with polydipsia, polyuria, and weight loss.
Management of dm in ckd
Diabetes is the leading cause of end-stage renal disease (ESRD), accounting for over 50% of new ESRD cases. Strict control of blood pressure, blood sugar, cholesterol, and protein in the urine can help prevent or delay kidney damage in patients with diabetes. For patients with diabetes and existing chronic kidney disease, careful management of medications, diet, anemia, bone disease, and other comorbidities is needed. Dialysis or kidney transplantation may be required as kidney function declines.
4 chf
Congestive heart failure occurs when the heart is unable to pump enough blood to meet the body's needs. There are two main types: systolic, where the heart's pumping action is weakened, and diastolic, where the heart stiffens and does not relax properly. Compensatory responses like hypertrophy can initially help but eventually worsen the heart's function. Severity is classified from mild limitations to symptoms at rest. Common drugs used are diuretics, ACE inhibitors, beta-blockers, and cardiac glycosides like digoxin which increase contractility by altering ion transport.
Cardiac Glycosides - drdhriti
This document discusses cardiac glycosides, which are drugs that increase the force of contraction of the heart without increasing oxygen consumption. It specifically focuses on digitalis, which is derived from foxglove. Digitalis increases myocardial contractility in a failing heart, improving cardiac output. It acts by increasing the intracellular calcium levels in cardiac muscle cells. The document covers the chemistry, pharmacology, mechanisms of action, effects on cardiac electrophysiology, pharmacokinetics, uses, and adverse effects of digitalis and other cardiac glycosides in detail over several pages.
Anti hypertensives
Basic must know things about Anti Hypertensive drugs including the recent JNC-8 classification and protocols for treating Hypertension with various co-morbid condition.
Dipeptidyl peptidase inhibitors(DPP-IV): A deep insight
This presentation deals with DPP-IV inhibitors, that are implicated for use in diabetes mellitus. Generalized pharmacology, including a precise insight into individual drugs have been elucidated.
Hypolipidemic drugs
This document discusses hypolipidaemic drugs and plasma expanders. It begins by introducing cardiovascular diseases and dyslipidemia as major causes of morbidity and mortality. It then describes the classification, metabolism, and disorders of lipoproteins. The main sections discuss the pharmacotherapy of hyperlipidemias including statins, fibrates, nicotinic acid, ezetimibe, and other agents. Adverse effects and guidelines for use are provided. Management of shock includes types of shock and treatment approaches for hypovolaemic, cardiogenic, septic, anaphylactic, and neurogenic shock. Ideal properties and examples of plasma expanders like dextran are also summarized.
Recent advances in management of diabetes
This document discusses advances in pharmacotherapy for type 2 diabetes. It describes several classes of oral and injectable drugs used to treat diabetes, including:
- Biguanides, sulfonylureas, meglitinides, DPP-4 inhibitors, TZDs, alpha-glucosidase inhibitors, and newer insulins for oral medications.
- GLP-1 agonists, amylin analogues for injectable medications.
It also discusses several potential future drug targets for type 2 diabetes treatment, including SGLT2 inhibitors, dual PPAR agonists, glucokinase activators, and anti-CD3 monoclonal antibodies. The document focuses on enhancing insulin secretion
Beta blockers
Beta receptor blockers are a class of drugs that are commonly used to treat cardiovascular conditions by blocking beta-1 and beta-2 receptors. They have several therapeutic uses including hypertension, congestive heart failure, angina, myocardial infarction, and cardiac arrhythmias. They work by decreasing heart rate, contractility, and blood pressure. Common side effects include fatigue, bronchospasm, and metabolic abnormalities. First generation blockers are non-selective while later generations are more cardioselective. Carvedilol is used for heart failure, atenolol for hypertension, and esmolol for emergencies. Propranolol is effective for migraine prevention. Timolol eye drops are used for glaucoma treatment by decreasing
B blockers
This document summarizes beta blockers, including their mechanism of action, classification, properties, uses, adverse effects and drug interactions. Beta blockers work by blocking beta receptors and inhibiting the adrenergic response. They are classified as first, second or third generation, and can be selective for beta 1 receptors or non-selective. Common uses include hypertension, angina, arrhythmias, migraine prophylaxis and anxiety. Side effects include bradycardia, bronchospasm and hypoglycemia. Drug interactions can occur pharmacokinetically or pharmacodynamically with drugs like digoxin. Overdose treatment involves atropine, pacing and glucagon administration.
Treatment of Diabetes Mellitus
The document discusses modern methods for treating diabetes mellitus, including the alphabet strategy, management of type 2 diabetes, and nutritional/physical activity principles. It outlines the plan of lecture topics which include the alphabet strategy, type 2 DM management, nutritional care, phytotherapy, physical activity, oral hypoglycemic agents, insulin therapy, insulin pump therapy, and complications of insulin therapy. A clinical case study is also presented of a patient with type 2 diabetes that may require starting an oral antidiabetic agent.
Pharmacology of corticosteroids
Presentation for Medical undergraduates for teaching pharmacology. It deals with Physiology of steroid hormones and their action along with agents which are used therapeutically with their action, adverse effects and therapeutic uses.
Antihypertensives - drdhriti
This document summarizes several classes of antihypertensive drugs, including their mechanisms of action and effects. It discusses diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, alpha-blockers, centrally acting drugs, and vasodilators. For each class, it describes their advantages and disadvantages in treating hypertension, as well as recommendations for use.
Sulfonylureas for Diabetes: A deep insight
This powerpoint presentation solely deals with Sulfonylureas, that come under Insulin secretagogues. Their complete pharmacological profile, with pharmacovigilance parameters, important catchpoints and mnemonics have been explained.
Diabetes Mellitus
Diabetes Mellitus is a group of disorders characterized by high levels of blood glucose in the body which is a result from the defects caused by insulin production, insulin action and sometimes both.
Presentation on diabetes
Diabetes is a disease that occurs when your blood glucose, also called blood sugar, is too high. Blood glucose is your main source of energy and comes from the food you eat. Insulin, a hormone made by the pancreas, helps glucose from food get into your cells to be used for energy. Sometimes your body doesn’t make enough—or any—insulin or doesn’t use insulin well. Glucose then stays in your blood and doesn’t reach your cells.
More Related Content
What's hot
Anti diabetic drugs by Sanan Edrees
1) There are several classes of anti-diabetic drugs that treat diabetes mellitus by lowering blood glucose levels, including insulin secretagogues, insulin sensitizers, alpha-glucosidase inhibitors, and DPP-4 inhibitors.
2) Insulin secretagogues like sulfonylureas stimulate insulin release from the pancreas. Insulin sensitizers like biguanides and thiazolidinediones improve target cell response to insulin without increasing secretion.
3) Alpha-glucosidase inhibitors prevent carbohydrate digestion and absorption, reducing post-meal blood sugar spikes. DPP-4 inhibitors prolong incretin hormone activity, increasing insulin release and reducing glucagon levels in response to meals.
Corticosteroids
This ppt discusses pharmacological actions, toxic effects and clinical applications of corticosteroids. It also mentions precations to be taken while using steroids
Pharmacology of antidiabetic drugs
This document summarizes a lecture on pharmacology of antidiabetic drugs. It begins with an introduction to diabetes mellitus and its classification into four main types: type 1 characterized by insulin deficiency; type 2 characterized by insulin resistance and relative insulin deficiency; type 3 characterized by other specific causes; and type 4 or gestational diabetes. It then discusses the mechanisms and pharmacokinetics of various classes of antidiabetic drugs including insulin, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors and incretin mimetics. Adverse effects including hypoglycemia are also summarized.
Sodium glucose co transporter( SGLT2) Inhibitors
This document discusses sodium-glucose co-transporter 2 (SGLT2) inhibitors, a new class of drugs for treating type 2 diabetes. SGLT2 inhibitors work by blocking glucose reabsorption in the kidney, increasing urinary glucose excretion in a glucose-dependent manner. Three SGLT2 inhibitors have been approved by the FDA - canagliflozin, dapagliflozin, and empagliflozin. SGLT2 inhibitors offer advantages over other anti-diabetic drugs in that they are non-insulin dependent and can be used throughout the course of diabetes. However, long-term safety studies are still needed to fully assess their risk-benefit profile.
Beta blockers
Lecture on beta blockers their classification, therapeutic uses, adverse effects , contraindications.
Beta 2 agonists
This document outlines the structure and function of beta-2 agonists used to treat asthma. It discusses how modifications to the chemical structure can prolong the duration of action. It also describes the intracellular signaling pathway of beta-2 agonists and their mechanisms of action, including relaxation of airway smooth muscle. The document summarizes the pharmacologic attributes and differences between short-acting beta-2 agonists like albuterol and long-acting ones like formoterol and salmeterol. It discusses potential non-bronchodilator effects and issues of tolerance with regular use. The document concludes by outlining some clinical applications and safety studies of beta-2 agonists.
Pharmacotherapy of diabetes mellitus
This document summarizes the pharmacotherapy of diabetes mellitus. It discusses the classification, diagnosis, and pathophysiology of diabetes. It also describes the types of insulin preparations including human insulin, insulin analogs, and their mechanisms of action and indications. The document provides examples of insulin dosing regimens for type 1 diabetes, including an example case of calculating the initial daily insulin dose for a 14-year-old patient presenting with polydipsia, polyuria, and weight loss.
Management of dm in ckd
Diabetes is the leading cause of end-stage renal disease (ESRD), accounting for over 50% of new ESRD cases. Strict control of blood pressure, blood sugar, cholesterol, and protein in the urine can help prevent or delay kidney damage in patients with diabetes. For patients with diabetes and existing chronic kidney disease, careful management of medications, diet, anemia, bone disease, and other comorbidities is needed. Dialysis or kidney transplantation may be required as kidney function declines.
4 chf
Congestive heart failure occurs when the heart is unable to pump enough blood to meet the body's needs. There are two main types: systolic, where the heart's pumping action is weakened, and diastolic, where the heart stiffens and does not relax properly. Compensatory responses like hypertrophy can initially help but eventually worsen the heart's function. Severity is classified from mild limitations to symptoms at rest. Common drugs used are diuretics, ACE inhibitors, beta-blockers, and cardiac glycosides like digoxin which increase contractility by altering ion transport.
Cardiac Glycosides - drdhriti
This document discusses cardiac glycosides, which are drugs that increase the force of contraction of the heart without increasing oxygen consumption. It specifically focuses on digitalis, which is derived from foxglove. Digitalis increases myocardial contractility in a failing heart, improving cardiac output. It acts by increasing the intracellular calcium levels in cardiac muscle cells. The document covers the chemistry, pharmacology, mechanisms of action, effects on cardiac electrophysiology, pharmacokinetics, uses, and adverse effects of digitalis and other cardiac glycosides in detail over several pages.
Anti hypertensives
Basic must know things about Anti Hypertensive drugs including the recent JNC-8 classification and protocols for treating Hypertension with various co-morbid condition.
Dipeptidyl peptidase inhibitors(DPP-IV): A deep insight
This presentation deals with DPP-IV inhibitors, that are implicated for use in diabetes mellitus. Generalized pharmacology, including a precise insight into individual drugs have been elucidated.
Hypolipidemic drugs
This document discusses hypolipidaemic drugs and plasma expanders. It begins by introducing cardiovascular diseases and dyslipidemia as major causes of morbidity and mortality. It then describes the classification, metabolism, and disorders of lipoproteins. The main sections discuss the pharmacotherapy of hyperlipidemias including statins, fibrates, nicotinic acid, ezetimibe, and other agents. Adverse effects and guidelines for use are provided. Management of shock includes types of shock and treatment approaches for hypovolaemic, cardiogenic, septic, anaphylactic, and neurogenic shock. Ideal properties and examples of plasma expanders like dextran are also summarized.
Recent advances in management of diabetes
This document discusses advances in pharmacotherapy for type 2 diabetes. It describes several classes of oral and injectable drugs used to treat diabetes, including:
- Biguanides, sulfonylureas, meglitinides, DPP-4 inhibitors, TZDs, alpha-glucosidase inhibitors, and newer insulins for oral medications.
- GLP-1 agonists, amylin analogues for injectable medications.
It also discusses several potential future drug targets for type 2 diabetes treatment, including SGLT2 inhibitors, dual PPAR agonists, glucokinase activators, and anti-CD3 monoclonal antibodies. The document focuses on enhancing insulin secretion
Beta blockers
Beta receptor blockers are a class of drugs that are commonly used to treat cardiovascular conditions by blocking beta-1 and beta-2 receptors. They have several therapeutic uses including hypertension, congestive heart failure, angina, myocardial infarction, and cardiac arrhythmias. They work by decreasing heart rate, contractility, and blood pressure. Common side effects include fatigue, bronchospasm, and metabolic abnormalities. First generation blockers are non-selective while later generations are more cardioselective. Carvedilol is used for heart failure, atenolol for hypertension, and esmolol for emergencies. Propranolol is effective for migraine prevention. Timolol eye drops are used for glaucoma treatment by decreasing
B blockers
This document summarizes beta blockers, including their mechanism of action, classification, properties, uses, adverse effects and drug interactions. Beta blockers work by blocking beta receptors and inhibiting the adrenergic response. They are classified as first, second or third generation, and can be selective for beta 1 receptors or non-selective. Common uses include hypertension, angina, arrhythmias, migraine prophylaxis and anxiety. Side effects include bradycardia, bronchospasm and hypoglycemia. Drug interactions can occur pharmacokinetically or pharmacodynamically with drugs like digoxin. Overdose treatment involves atropine, pacing and glucagon administration.
Treatment of Diabetes Mellitus
The document discusses modern methods for treating diabetes mellitus, including the alphabet strategy, management of type 2 diabetes, and nutritional/physical activity principles. It outlines the plan of lecture topics which include the alphabet strategy, type 2 DM management, nutritional care, phytotherapy, physical activity, oral hypoglycemic agents, insulin therapy, insulin pump therapy, and complications of insulin therapy. A clinical case study is also presented of a patient with type 2 diabetes that may require starting an oral antidiabetic agent.
Pharmacology of corticosteroids
Presentation for Medical undergraduates for teaching pharmacology. It deals with Physiology of steroid hormones and their action along with agents which are used therapeutically with their action, adverse effects and therapeutic uses.
Antihypertensives - drdhriti
This document summarizes several classes of antihypertensive drugs, including their mechanisms of action and effects. It discusses diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, alpha-blockers, centrally acting drugs, and vasodilators. For each class, it describes their advantages and disadvantages in treating hypertension, as well as recommendations for use.
Sulfonylureas for Diabetes: A deep insight
This powerpoint presentation solely deals with Sulfonylureas, that come under Insulin secretagogues. Their complete pharmacological profile, with pharmacovigilance parameters, important catchpoints and mnemonics have been explained.
What's hot (20)
Dipeptidyl peptidase inhibitors(DPP-IV): A deep insight
Dipeptidyl peptidase inhibitors(DPP-IV): A deep insight
Similar to Oral antidiabetic drugs (for primary care physician
Diabetes Mellitus
Diabetes Mellitus is a group of disorders characterized by high levels of blood glucose in the body which is a result from the defects caused by insulin production, insulin action and sometimes both.
Presentation on diabetes
Diabetes is a disease that occurs when your blood glucose, also called blood sugar, is too high. Blood glucose is your main source of energy and comes from the food you eat. Insulin, a hormone made by the pancreas, helps glucose from food get into your cells to be used for energy. Sometimes your body doesn’t make enough—or any—insulin or doesn’t use insulin well. Glucose then stays in your blood and doesn’t reach your cells.
Diabetes Mellitus And Its Treatment
This document discusses diabetes mellitus (DM), including the different types of DM, symptoms, causes, long-term effects, risk factors, and management strategies. It defines DM as a metabolic disorder characterized by high blood glucose levels due to defects in insulin production or action. The three main types of DM are type 1, type 2, and gestational diabetes. Management involves lifestyle changes like diet and exercise, oral medications, and sometimes insulin therapy, with the goal of controlling blood glucose levels to minimize health complications.
Diabetes mellitus ; signs, symptoms and management
The document discusses the pathophysiology and treatment of diabetes mellitus, outlining the different types of diabetes, prevalence rates, diagnostic criteria, treatment goals, and classes of antidiabetic medications. Management involves both nonpharmacologic approaches like diet and exercise as well as pharmacologic therapies including insulin, metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. The goal of treatment is to control blood glucose levels, lower HbA1c, prevent acute and chronic complications, and maintain
DIABETES MELLITUS AN OVERVIEW.pptx
This document provides an overview of diabetes mellitus (DM), including its classification, etiology, epidemiology, clinical manifestations, complications, diagnosis, and management. There are four main types of DM: type 1 caused by autoimmune destruction of beta cells; type 2 resulting from insulin resistance and relative insulin deficiency; gestational DM during pregnancy; and secondary DM caused by other conditions. Management involves lifestyle changes and medications like insulin, sulfonylureas, metformin, and others to control symptoms and prevent complications. The goals are to reduce risks and promote overall well-being.
Diabetes mellitus
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action.
Diabetes mellitus
Hyperglycemia
metabolism
health
Health
Diabetes mellitus management
Definition of diabetes - introduction - classification of diabetes - etiology of diabetes type 1 and type 2- risk factors for diabetes - diagnosis of diabetes - clinical manifestations of diabetes type 1 and type 2- investigations for diabetes - treatment of diabetes - non-pharmacological treatment and pharmacological treatment - pharmacotherapy of type 1 and type 2 - acute complications of diabetes and treatment
Current Management of Diabetes Mellitus by Ghaza khan.
This presentation covers:
Introduction
causes
Types
Pathophysiology
signs and symptoms
Risk factors
complications
Epidemiology
Diagnosis
Management
Current management of Diabetes Mellitus by Ghaza khan.
INTRODUCTION
TYPES
CAUSES
EPIDEMIOLOGY
RISK FACTORS
SIGN AND SYMPTOMS
COMPLICATIONS
MANAGEMENT
Pharmacotherapy and Management of Diabetes.pptx
This document discusses drug therapy and management of diabetes. It begins by defining pharmacotherapy and its goals in achieving therapeutic effects while managing drug administration safely and effectively. It then classifies and describes diabetes, noting the two main types, symptoms, and targets for treatment. Non-pharmacological measures like diet, exercise and lifestyle changes are recommended initially, along with patient education. If targets are not met, oral anti-diabetic drugs and insulin therapy are used. Common drug classes discussed include biguanides, thiazolidinediones, alpha-glucosidase inhibitors, incretin mimetics, and insulin. The document emphasizes a multi-faceted approach to diabetes management through medical nutrition therapy, physical activity, medication adherence,
Treatment of type ii diabetes by Husna Saqlain
Pancreas makes a hormone called insulin. It helps your cells turn glucose, a type of sugar, from the food you eat into energy. Diabetes happens when one or more of the following occurs:
Your pancreas does not make any insulin.
Your pancreas makes very little insulin.
Your body does not respond the way it should to insulin
An overview of anti diabetic drugs and management of diabetic complications
This document provides an overview of anti-diabetic drugs and management of diabetic complications. It discusses the different types of diabetes and goals of treatment. For type 1 diabetes, various insulin preparations are described based on their onset, peak and duration of action. For type 2 diabetes, 6 classes of oral medications are outlined, including biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, and meglitinides. Each drug class is explained in terms of mechanism of action, dosing, efficacy and side effects. Management of complications also aims to prevent progression of microvascular and macrovascular disorders.
OHA.pptx
The document discusses various types of oral hypoglycemic agents (OHAs) used to treat type 2 diabetes mellitus (T2DM). It describes the classifications of OHAs including biguanides like metformin, sulphonylureas, meglitinides, thiazolidinediones, and others. For each class, it provides details on mechanisms of action, pharmacokinetics, dosing, side effects, and contraindications. Metformin and sulphonylureas have been used the longest and remain first-line treatment options, though each class has advantages and disadvantages discussed in the document.
Oral anti diabetic drugs
Diabetes mellitus is a clinical syndrome characterized by an increase in plasma blood glucose (hyperglycemia).
Diabetes has many causes but is most commonly due to type 1 or type 2 diabetes
Metformin Case Study
Cynthia is experiencing hypoglycemia due to taking a sulfonylurea medication. The doctor diagnoses her with hypoglycemia and recommends changing her medication from a sulfonylurea to Januvia to avoid further hypoglycemic events. Patient response can vary to different medications, so it is important to monitor for risks associated with specific medications.
SEMINAR PRESENTATION.pptx dmmm.pptx
This document outlines a seminar presentation on diabetes mellitus. It includes an introduction to diabetes, definitions of the different types of diabetes, pathophysiology, risk factors, signs and symptoms, diagnosis, and management of complications. Type 1 diabetes results from autoimmune destruction of insulin-producing cells while type 2 involves insulin resistance and relative insulin deficiency. Treatment involves lifestyle changes, oral medications, insulin therapy, and managing complications such as hypoglycemia, ketoacidosis, neuropathy, and nephropathy.
Oral hypoglycemic agent
Manish yadav .M Pharm First year
Pharmacology . Under -guidence of
Professor Dr. Govind Singh .
M.D.University Rohtak
Department Pharmaceutical science
DM-1 (10).pptx
1) Diabetes mellitus is a metabolic disorder characterized by hyperglycemia due to defects in insulin secretion, insulin action, or both. It is classified into type 1, type 2, gestational diabetes, and other specific types.
2) Type 1 diabetes is caused by autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency. Type 2 diabetes involves insulin resistance and relative insulin deficiency.
3) Treatment of diabetes involves lifestyle modifications, glucose monitoring, and pharmacologic therapies including insulin and various oral hypoglycemic agents. The goals of treatment are to achieve optimal glycemic control and prevent complications.
Antidiabetic_Drugs_2.ppt
This document discusses antidiabetic drugs used to treat diabetes mellitus. It defines diabetes as a disorder of carbohydrate metabolism resulting from inadequate insulin production or utilization. The two main types of diabetes, type 1 and type 2, are described. Type 1 is an autoimmune disorder destroying pancreatic beta cells, while type 2 involves insulin resistance and relative insulin deficiency. Common antidiabetic drug classes discussed include insulin, sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, and meglitinides. Specific medications within each class are named and their mechanisms of action and side effects are summarized. Complications of uncontrolled diabetes like diabetic ketoacidosis and hyperosmolar
Oral hypoglycemic agents
introduction to oral hypoglycemic agents with description about sulphonylurea and glinides along with their MOA, indication, side effects and brand name
Similar to Oral antidiabetic drugs (for primary care physician (20)
Diabetes mellitus ; signs, symptoms and management
Diabetes mellitus ; signs, symptoms and management
Current Management of Diabetes Mellitus by Ghaza khan.
Current Management of Diabetes Mellitus by Ghaza khan.
Current management of Diabetes Mellitus by Ghaza khan.
Current management of Diabetes Mellitus by Ghaza khan.
An overview of anti diabetic drugs and management of diabetic complications
An overview of anti diabetic drugs and management of diabetic complications
More from Domina Petric
Tetrodotoxin
Tetrodotoxin is a potent neurotoxin found in marine animals like pufferfish. It blocks sodium channels, preventing action potentials and paralyzing neurons and muscles. Poisoning symptoms range from numbness to respiratory failure and death. The toxin is produced by various bacteria in marine life. While rare, poisoning is more common where pufferfish is regularly consumed. There is no antidote, so treatment focuses on supportive care and monitoring until the toxin is cleared from the body.
ECG S
1) The Sgarbossa criteria provide guidelines for diagnosing acute myocardial infarction in patients with left bundle branch block (LBB) or ventricular paced rhythm on electrocardiogram (ECG), as these conditions can obscure ECG changes.
2) The original Sgarbossa criteria included three criteria involving concordant or discordant ST segment changes greater than 1mm. The modified criteria expanded this to include proportionally excessive discordant ST elevation.
3) Different types of STEMI are described based on the location of maximal ST elevation, including anterior, inferior, lateral, posterior, and right ventricular STEMI, each with characteristic ECG patterns.
ECG I
This document discusses interventricular conduction delay and raised intracranial pressure as seen on electrocardiograms (ECGs). It defines interventricular conduction delay and lists various causes including fascicular blocks, bundle branch blocks, ventricular hypertrophy, dilatation, electrolyte abnormalities, toxins, pre-excitation, and arrhythmogenic cardiac conditions. It then discusses raised intracranial pressure and the associated ECG findings of widespread T-wave inversions, QT prolongation, and bradycardia as part of the Cushing reflex, indicating imminent brainstem herniation. Massive intracranial hemorrhages such as subarachnoid hemorrhage are the most common causes
ECG H
The document discusses various electrolyte abnormalities and their ECG manifestations, including hypercalcemia, hypocalcemia, hyperkalemia, hypokalemia, hypomagnesia, hyperthyroidism, hypothyroidism, and hypothermia. For each condition, it provides the normal and abnormal ranges for the electrolyte levels and describes the associated ECG changes such as peaked T waves, QT prolongation, low QRS voltage, bradycardia, and arrhythmias. The document serves as a reference for clinicians to recognize ECG patterns caused by electrolyte and endocrine abnormalities.
ECG F
1) Fascicular ventricular tachycardia is the most common form of idiopathic ventricular tachycardia originating from the left ventricle. It typically presents in young patients without structural heart disease.
2) It has characteristic ECG features including a monomorphic ventricular rhythm with fusion complexes and AV dissociation. The QRS duration is between 100-140 ms with a short RS interval of 60-80 ms. It also shows a right bundle branch block pattern and axis deviation.
3) Posterior fascicular ventricular tachycardia, which arises near the left posterior fascicle, shows a right bundle branch block pattern with left axis deviation. Anterior fascicular ventricular tachycardia arises
ECG E
The document discusses several electrocardiogram (ECG) findings and rhythms including ectopic atrial tachycardia, atrial tachycardia, electrical alternans seen in massive pericardial effusion which produces low QRS voltage, electrical alternans and tachycardia, escape rhythms like junctional escape rhythms where the pacemaker rate decreases down the conducting system, and ventricular escape rhythms. It also discusses the terminology of junctional rhythms and includes literature references.
ECG D
The document discusses De Winter's T waves, which are characterized by three key findings on ECG: upsloping ST depression in precordial leads, tall symmetric T waves in precordial leads, and ST elevation in aVR. It also summarizes the ECG patterns seen in dextrocardia, including right axis deviation, positive complexes in aVR, and dominant S waves in precordial leads. Finally, it outlines the ECG features of digoxin effect and toxicity, such as biphasic T waves, shortened QT, and the dysrhythmia of supraventricular tachycardia with a slow ventricular response seen in digoxin toxicity.
ECG C
Massive carbamazepine overdose of more than 50 mg/kg can cause cardiotoxicity due to sodium channel blockade, which may be detectable on ECG as subtle QRS widening or first-degree AV block. Dilated cardiomyopathy is characterized by ventricular dilatation and reduced ejection fraction below 40%, commonly presenting with symptoms of biventricular failure. Chronic obstructive pulmonary disease can cause prominent P waves in inferior leads, exaggerated ST segments, low QRS voltage especially in V4-V6, and may show an SV1-SV2-SV3 pattern.
ECG B
- Benign early repolarization shows concave ST elevation less than 2 mm with no progression over time, most prominent in V2-V5. Notching at the J-point and concordant T-waves are also seen.
- Beta-blocker and calcium channel blocker toxicity can cause prolonged PR interval and bradycardia. Propranolol toxicity specifically causes QRS widening and positive R' wave in aVR. Sotalol toxicity causes QT prolongation and risk of Torsades de Pointes.
- Bifascicular block is a combination of right bundle branch block with either left anterior or posterior fascicular block, and can be caused by ischemia, hypertension or other
ECG A: AVNRT, AVRT
This document discusses atrioventricular nodal reentrant tachycardia (AVNRT). It states that AVNRT is the most common cause of palpitations in structurally normal hearts. It can occur spontaneously or be provoked. There are three main types - slow-fast AVNRT which is most common and shows no visible P waves, fast-slow AVNRT where P waves are visible after the QRS, and slow-slow AVNRT where P waves appear before the QRS. The tachycardia rate is typically between 140-280 beats per minute and is regular. AVNRT occurs due to a reentry circuit within the atrioventricular node.
ECG A: AV blocks
This document summarizes different types of atrioventricular (AV) blocks seen on electrocardiograms (ECGs). It describes first-degree AV block as a PR interval over 200ms. Second-degree AV block, Mobitz type I (Wenckebach phenomenon) shows progressive PR prolongation until a blocked pulse. Mobitz type II shows intermittent non-conducted pulses without PR prolongation. High-grade second-degree AV block has a P:QRS ratio of 3:1 or higher, with an extremely slow ventricular rate. Third-degree or complete heart block shows no relationship between atrial and ventricular rates. Causes include myocardial infarction, drugs, and conduction system disease. Treatment ranges from
ECG A: first part.
This document provides an overview of several cardiac arrhythmias and conditions including:
1. Accelerated idioventricular rhythm (AIVR), which results when an ectopic ventricular pacemaker exceeds the sinus node rate. AIVR is seen post-myocardial infarction and features a regular rhythm between 50-110 bpm with three or more QRS complexes.
2. Atrial flutter, a supraventricular tachycardia caused by a reentry circuit in the right atrium with a rate of around 300 bpm. The ventricular rate is determined by AV conduction.
3. Atrial fibrillation, the most common sustained arrhythmia characterized by irregularly irregular rhythm without
Cardiorenal syndrome
1) Cardiorenal syndrome commonly occurs in patients with acute decompensated heart failure and is associated with poor outcomes. It involves a complex interaction between hemodynamic alterations and activation of neurohormonal systems that affects both the heart and kidneys.
2) There are five types of cardiorenal syndrome classified based on the inciting cardiac or renal event and the affected secondary organs. Type 1 is acute cardiorenal syndrome due to acute worsening of cardiac function leading to kidney injury.
3) Loop diuretics are the mainstay of treatment for congestion in heart failure but aggressive diuresis may worsen kidney function. Other therapies discussed include inotropic agents, vasopressin antagonists
Categorization of risks and benefits (food additives)
The document discusses various categories of risks associated with food, including foodborne hazards of microbial origin, nutritional hazards, environmental contaminants, naturally occurring toxicants, and food additives. It notes that foodborne diseases of microbial origin pose the greatest risks. Nutritional hazards can arise from deficiencies or excesses. Environmental contaminants can enter the food supply from industrial or natural sources. Naturally occurring toxicants are found in some foods. Food additives present minimal risks when consumed within permitted levels. The document also outlines categories of potential benefits from foods, including health benefits, supply benefits, hedonic benefits, and convenience benefits.
Benefits and risks of additives
This document discusses the benefits and risks of food additives. The benefits include making foods safer, more nutritious, and longer lasting through the use of preservatives and antioxidants. Additives also provide greater variety of foods and lower prices. However, there are also risks. There is a lack of data on the long term health effects of combinations of additives. Some additives are associated with "junk foods" that are low in nutrients. While direct toxic effects are unlikely at legal levels, some individuals may have hypersensitivity reactions. Some animal studies also indicate potential cancer and reproductive issues, but no direct evidence in humans. The risks must be weighed against the benefits on a case by case basis.
Types of food additives
The document discusses different types of food additives and how they are classified. It describes preservatives like antimicrobials, antioxidants and antibrowning agents. Nutritional additives add vitamins, minerals and fiber. Coloring agents and flavors are used to enhance appearance and taste. Texturizing agents modify texture and mouthfeel. Additives are identified by International Numbering System codes or E numbers from the European Union.
Effector phase in immune mediated drug hypersensitivity
This document discusses antibody-mediated and T cell-mediated drug hypersensitivity. It describes how drugs can act as haptens and stimulate T and B cell responses, leading to IgE production and immediate hypersensitivity reactions. It also discusses the p-i concept where drugs can directly interact with T cell receptors and cause reactions without prior sensitization, particularly in the skin which contains many resident immune cells.
T cell stimulation by drugs
1. Small molecule drugs can become immunogenic by undergoing bioactivation into chemically reactive metabolites that covalently bind to proteins, forming hapten-carrier complexes.
2. These complexes are then processed and presented by antigen presenting cells to T cells, stimulating an adaptive immune response.
3. Whether a humoral or cellular immune response develops depends on which proteins are modified by the hapten and whether they are soluble or cell-bound.
More from Domina Petric (20)
Categorization of risks and benefits (food additives)
Categorization of risks and benefits (food additives)
Effector phase in immune mediated drug hypersensitivity
Effector phase in immune mediated drug hypersensitivity
Recently uploaded
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Learn about body grief and ways to cope with it. We will also explore methods to heal from this challenging experience.
Best Ayurvedic medicine for Gas and Indigestion
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Top-Vitamin-Supplement-Brands-in-India List
Swisschem Dermacare provides the Top 10 Vitamin Supplement Brands in India. To know more about us give us call at our official number
The Electrocardiogram - Physiologic Principles
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Journal Article Review on Rasamanikya
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
A Classical Text Review on Basavarajeeyam
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Recently uploaded (20)
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Oral antidiabetic drugs (for primary care physician
- 1. Oral antidiabetic drugs (for primary care physician) Domina Petric, MD
- 3. It is indicated for adults, adolescents and children more than 10 years old. It is indicated for treatment of diabetes mellitus type 2 (DMT2) when exercise and diet are not sufficient. It is especially indicated for the patients with excessive body weigh. Metformin
- 4. Metformin
- 5. hypersensitivity diabetic ketoacidosis kidney failure (ClCr<60 mL/min) dehidration severe infections shock heart or respiratory insufficiency recent myocardial infarction liver insufficiency acute alchohol intoxication alchoholism Contraindications
- 6. Lactacidosis
- 7. Interactions
- 8. Not recommended in pregnancy and lactation! Pregnancy and lactation
- 10. Indicated for DMT2 (insulin independent type of diabetes) patients in monotherapy or in combination with metformin. Start dose is 1,75 mg up to 3,5 mg per os a day. Maximum dose is 10,5 mg per os a day. Drug is taken with full glass of water before meal. In case of higher doses, the total dose is divided in ratio 2:1 = in the morning : in the evening. Glibenclamide
- 11. o hypersensitivity o insulin dependent diabetes o diabetic ketoacidosis o diabetic coma o severe kidney or liver damage o treatment with bosentan o pregnancy o lactation Contraindications
- 12. Very good for middle aged or older patients. Start dose is 15 mg per os a day during lunch. Maximum dose is 120 mg per os a day divided in two or three doses. It is not recommended for children and adolescents. Contraindications are: hypersensitivity insulin dependent diabetes diabetic coma severe liver damage infections before surgical procedures Gliquidone Not recommended during pregnancy and lactation.
- 15. Indicated for DMT2 patients that are not well regulated with metformin or can not take it (or other drugs). Start dose is 50 mg per os three times a day. Maintenance dose is 100 mg per os three times a day. Maximum dose is 200 mg per os three times a day. The drug is taken with the glass of water before meal or during the meal, chewed. Not recommended for children under the age of 18. Contraindications are hypersensitivity, inflammatory bowel disease, bowel obstruction, severe liver or kidney damage (ClCr<25 mL/min). Acarbose
- 17. It is indicated for DMT2 patients as second or third line therapy: 1) Monotherapy: adults that can not take metformin. 2) Double peroral therapy: with metformin (in adults when metformin as monotherapy is not sufficient) OR with sulphonylureas (when metformin is contraindicated). 3) Triple peroral therapy: with metformin and sulphonylureas OR with insulin therapy. Start dose is 15 mg or 30 mg per os once a day. Maximum dose is 45 mg. Contraindications are hypersensitivity, heart failure (NYHA I to IV), liver damage, diabetic ketoacidosis, macroscopic haematuria, actual or history of urinary bladder carcinoma. Pioglitazone